Generic Name and Formulations:
Polyethylene glycol 3350 420g, sodium bicarbonate 5.72g, sodium chloride 11.2g, potassium chloride 1.4g; per 4L of soln; pwd for reconstitution; cherry, lemon-lime, orange, or pineapple flavor.
Braintree Laboratories, Inc.
Indications for NuLYTELY:
Bowel cleansing before colonoscopy.
May consume water or clear liquids during and after completion of bowel prep up until 2hrs before procedure. Drink 240mL orally every 10 mins or 20–30mL/min by NG tube until rectal effluent is clear or 4L consumed. May interrupt if severe GI disturbances occur.
<6 months: not recommended. ≥6 months: May consume water or clear liquids during and after completion of bowel prep up until 2hrs before procedure. Drink 25mL/kg per hour orally or by NG tube until rectal effluent is clear or 4L consumed. May interrupt if severe GI disturbances occur.
GI obstruction. Bowel perforation. Gastric retention. Ileus. Toxic colitis or megacolon.
Not for direct ingestion. Correct fluid/electrolyte abnormalities before use. History of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF, or cardiomyopathy: increased risk of arrhythmias; consider ECGs at pre-dose and post-colonoscopy. History or risk of seizures. Renal impairment; monitor baseline and post-colonoscopy electrolytes, creatinine, BUN. Inflammatory bowel disease. Rule out suspected GI obstruction/perforation before administering. Severe ulcerative colitis. Impaired gag reflex. Semi- or unconscious patients. Risk of regurgitation or aspiration. Monitor young children (<2yrs) for hypoglycemia. Maintain adequate hydration. Pregnancy (Cat.C). Nursing mothers.
Caution with drugs that increase risk of fluid/electrolyte abnormalities, arrhythmias or QT prolongation. Drugs that may lower the seizure threshold (eg, tricyclic antidepressants), alcohol or benzodiazepine withdrawal, known or suspected hyponatremia: may increase risk of seizures. Concomitant diuretics, ACE inhibitors, ARBs, NSAIDs; may affect renal function. Avoid concomitant stimulant laxatives (eg, bisacodyl, sodium picosulfate). Oral drugs administered within 1hr of start of Nulytely may not be absorbed.
Nausea, abdominal fullness and bloating, cramps, vomiting, anal irritation; seizures, arrhythmias, mucosal ulcerations and ischemic colitis. Children: also dehydration or hypokalemia.
Disposable jug (4L)—1
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Predictors of Opioid Overdose in High-Risk Users
- FDA to Review Long-Acting Treatment for Opioid Use Disorder
- Half of Patients Referred for Behavioral Treatment of Migraine Never Initiate Treatment
- Low-Dose Sumatriptan Injection Effective as Acute Migraine Treatment
- The Fight for Patient Privacy Under Big Data Analytics